I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod

Tadaaki Taniguchi, Japan R&D Head, AstraZeneca By Takashi Ebisawa After a major setback in an I/O combo trial last year, AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) notched up approval as a single-agent maintenance treatment for a previously untapped pool of Stage...read more